{"id":"risperidone-risperdal","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation"},{"rate":"40-50","effect":"Prolactin elevation (hyperprolactinemia)"},{"rate":"10-20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Metabolic syndrome"},{"rate":"1-5","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. This dual antagonism distinguishes it from typical antipsychotics and is associated with a lower risk of extrapyramidal side effects.","oneSentence":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:23.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Aggression and behavioral disturbances in dementia"}]},"trialDetails":[{"nctId":"NCT07490353","phase":"PHASE1","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-11-01","conditions":"Depression - Major Depressive Disorder, Anhedonia","enrollment":85},{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder","enrollment":524},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT04639960","phase":"NA","title":"Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome","status":"TERMINATED","sponsor":"University of Geneva, Switzerland","startDate":"2017-09-29","conditions":"22q11.2 Deletion Syndrome","enrollment":16},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT05779241","phase":"PHASE3","title":"Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2023-04-13","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":83},{"nctId":"NCT00830349","phase":"PHASE1","title":"Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT00829894","phase":"PHASE1","title":"Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02822092","phase":"","title":"Striatal Connectivity and Clinical Outcome in Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2016-07","conditions":"Psychotic Disorders","enrollment":196},{"nctId":"NCT00330551","phase":"PHASE4","title":"Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT02411526","phase":"PHASE1","title":"Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2015-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":60},{"nctId":"NCT00716755","phase":"NA","title":"Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2009-10","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":45},{"nctId":"NCT01171937","phase":"PHASE2","title":"Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-09","conditions":"Autism","enrollment":41},{"nctId":"NCT01451736","phase":"PHASE4","title":"Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":"Schizophrenia (Recent-onset)","enrollment":146},{"nctId":"NCT03837860","phase":"EARLY_PHASE1","title":"Reducing the Abuse of Opioids in Drug Users","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-04-01","conditions":"Opioid Abuse, Unspecified, Opioid Dependence","enrollment":3},{"nctId":"NCT00698022","phase":"PHASE1","title":"A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2008-11","conditions":"Healthy","enrollment":76},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT05179525","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone.","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2021-03-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT03955549","phase":"PHASE3","title":"Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial","status":"COMPLETED","sponsor":"Agiad Psychiatry Hospital","startDate":"2019-05-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":99},{"nctId":"NCT03978832","phase":"PHASE4","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-06-28","conditions":"Schizophrenia","enrollment":69},{"nctId":"NCT02918097","phase":"PHASE4","title":"Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2010-05","conditions":"Bipolar Disorder","enrollment":78},{"nctId":"NCT00221403","phase":"PHASE3","title":"Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT04587115","phase":"EARLY_PHASE1","title":"Reducing the Abuse Liability of Prescription Opioids","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-06-16","conditions":"Addiction","enrollment":15},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT01639872","phase":"PHASE4","title":"Clozapine for Cannabis Use in Schizophrenia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2013-05-01","conditions":"Schizophrenia, Cannabis Abuse, Cannabis Dependence","enrollment":49},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT00333177","phase":"PHASE4","title":"Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":92},{"nctId":"NCT02021201","phase":"PHASE4","title":"The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia","status":"TERMINATED","sponsor":"Birte Glenthoj","startDate":"2008-07","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT02063945","phase":"PHASE4","title":"Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2017-02-01","conditions":"Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder","enrollment":5},{"nctId":"NCT00622011","phase":"PHASE4","title":"Risperidone and Zotepine in the Treatment of Delirium","status":"TERMINATED","sponsor":"Changhua Christian Hospital","startDate":"2008-01","conditions":"Delirium","enrollment":5},{"nctId":"NCT02532491","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-05","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT03883204","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2015-01-01","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":115},{"nctId":"NCT00746252","phase":"NA","title":"Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2008-06","conditions":"Bipolar Disorder","enrollment":5},{"nctId":"NCT00515723","phase":"NA","title":"Glucose and Lipid Metabolism on Antipsychotic Medication","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus","enrollment":96},{"nctId":"NCT00056498","phase":"PHASE4","title":"Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-12","conditions":"Schizophrenia","enrollment":65},{"nctId":"NCT03302364","phase":"","title":"A Research in Pharmacogenomics and Accurate Medication of Risperidone","status":"UNKNOWN","sponsor":"Cui Yimin","startDate":"2017-10-22","conditions":"Schizophrenia, Mental Illness","enrollment":800},{"nctId":"NCT00573287","phase":"NA","title":"First Episode Schizophrenia and Cannabis-Related Disorder Study","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2006-06","conditions":"Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia","enrollment":14},{"nctId":"NCT03090503","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-06","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":200},{"nctId":"NCT00694707","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06-30","conditions":"Schizophrenia","enrollment":732},{"nctId":"NCT00148083","phase":"PHASE3","title":"Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2005-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":5},{"nctId":"NCT00130923","phase":"PHASE4","title":"Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-09","conditions":"Schizophrenia, Psychotic Disorders, Substance Abuse","enrollment":95},{"nctId":"NCT02472652","phase":"PHASE4","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Gazda, Thomas D., M.D., PC","startDate":"2015-06","conditions":"Sexual Dysfunction","enrollment":2},{"nctId":"NCT01686815","phase":"","title":"Cross-Sectional Iloperidone IVGTT","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-10","conditions":"Schizophrenia, Serious Mental Illness, Metabolic Syndrome","enrollment":37},{"nctId":"NCT02034253","phase":"","title":"Glutamate, Brain Connectivity and Duration of Untreated Psychosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-01","conditions":"Schizophrenia, Psychosis, Schizoaffective Disorder","enrollment":134},{"nctId":"NCT00245206","phase":"PHASE4","title":"Side Effects of Newer Antipsychotics in Older Adults","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2005-08","conditions":"Schizophrenia, Alzheimer's Disease, Dementia","enrollment":406},{"nctId":"NCT02456454","phase":"PHASE3","title":"Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2006-01","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT01516424","phase":"PHASE3","title":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2012-02","conditions":"Schizophrenia","enrollment":267},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02562287","phase":"PHASE4","title":"Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-10","conditions":"Bipolar Disorder","enrollment":54},{"nctId":"NCT01333072","phase":"PHASE4","title":"Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2011-07","conditions":"Autistic Disorder","enrollment":80},{"nctId":"NCT01878513","phase":"NA","title":"Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2009-09-23","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified","enrollment":88},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00205699","phase":"PHASE4","title":"Metabolic Effects of Antipsychotics in Children","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-04","conditions":"Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder","enrollment":144},{"nctId":"NCT00294255","phase":"PHASE4","title":"Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2003-03","conditions":"Bipolar Disorder","enrollment":45},{"nctId":"NCT01175135","phase":"PHASE2","title":"An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Schizophrenia","enrollment":259},{"nctId":"NCT00314327","phase":"PHASE4","title":"Optimizing Response in Psychosis Study","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2006-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":1},{"nctId":"NCT03220867","phase":"PHASE1","title":"Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants","status":"WITHDRAWN","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-12-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT03390712","phase":"","title":"Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection","status":"UNKNOWN","sponsor":"Réseau de Santé Vitalité Health Network","startDate":"2018-01-02","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":328},{"nctId":"NCT00314613","phase":"PHASE4","title":"Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-04","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT00939497","phase":"PHASE1","title":"Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00939926","phase":"PHASE1","title":"Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00571688","phase":"PHASE4","title":"Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2007-11","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT00796302","phase":"PHASE4","title":"Treatment of Severe Childhood Aggression (The TOSCA Study)","status":"COMPLETED","sponsor":"Michael Aman","startDate":"2008-08","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":168},{"nctId":"NCT00000317","phase":"PHASE2","title":"Early Phase II Trials for Cocaine Medication Development - 1","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1996-08","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":31},{"nctId":"NCT02538081","phase":"PHASE1, PHASE2","title":"Nicotinic Receptors and Schizophrenia","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2015-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00385801","phase":"PHASE2","title":"Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-09","conditions":"Cocaine Dependence","enrollment":31},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00178854","phase":"PHASE4","title":"Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2004-05","conditions":"Treatment Resistant Depression","enrollment":""},{"nctId":"NCT00435370","phase":"PHASE3","title":"Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-11","conditions":"Smoking Cessation, Schizophrenia","enrollment":179},{"nctId":"NCT01786239","phase":"NA","title":"Omega-3 Dietary Supplements in Schizophrenia","status":"COMPLETED","sponsor":"Delbert Robinson","startDate":"2013-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":50},{"nctId":"NCT02687984","phase":"PHASE1","title":"PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-02","conditions":"Schizophrenia","enrollment":44},{"nctId":"NCT02964923","phase":"","title":"Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-04","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT01140620","phase":"PHASE4","title":"Effects of Ketamine and Risperidone on Cognition","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2010-06","conditions":"Healthy Volunteers, Schizophrenia","enrollment":87},{"nctId":"NCT01295372","phase":"PHASE3","title":"Safety and Efficacy of Zicronapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-04","conditions":"Schizophrenia","enrollment":160},{"nctId":"NCT00423878","phase":"PHASE4","title":"Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2007-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":215},{"nctId":"NCT00320671","phase":"PHASE4","title":"Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2005-12","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT00399698","phase":"PHASE3","title":"Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.","status":"COMPLETED","sponsor":"Ohio State University","startDate":"1999-05","conditions":"Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD)","enrollment":30},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01844700","phase":"PHASE4","title":"1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure","enrollment":14},{"nctId":"NCT00140426","phase":"PHASE4","title":"A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2004-08","conditions":"Anorexia Nervosa","enrollment":41},{"nctId":"NCT02650102","phase":"PHASE1, PHASE2","title":"The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2013-01","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01977300","phase":"PHASE3","title":"Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01","conditions":"Bipolar I Disorder","enrollment":159},{"nctId":"NCT00176202","phase":"PHASE3","title":"Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2003-04","conditions":"Bipolar Disorder","enrollment":65},{"nctId":"NCT02593734","phase":"PHASE4","title":"Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana","status":"COMPLETED","sponsor":"University of Ghana Medical School","startDate":"2013-07","conditions":"Schizophrenia, Mood Disorders,, Anxiety Disorder","enrollment":139},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT00225498","phase":"NA","title":"Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2002-06","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT01119638","phase":"PHASE4","title":"Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone","status":"COMPLETED","sponsor":"Abarbanel Mental Health Center","startDate":"2008-04","conditions":"Agitation, Psychosis, Alzheimer's Disease","enrollment":40},{"nctId":"NCT02186769","phase":"PHASE1","title":"An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2014-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":16},{"nctId":"NCT01770600","phase":"NA","title":"Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2010-04","conditions":"Impulsivity, Active Suicidal Ideation, Depression","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"risperidone (Risperdal)","genericName":"risperidone (Risperdal)","companyName":"University of South Florida","companyId":"university-of-south-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}